Enabling pharmacogenomic clinical trials through sampling
Abstract
Discussion and output from the US FDA and the pharmaceutical industry from the Drug Information Association/FDA 5th Workshop in a series on pharmacogenomics entitled: ‘Generating and Weighing Evidence in Drug Development and Regulatory Decision Making’. A major topic area at the 5th FDA/Industry Workshop on Pharmacogenomics, February 2–4, 2010 in Bethseda (MD, USA), was enabling pharmacogenomic clinical trials through collection of future use samples. The importance of the collection of samples with permission for future analyses was affirmed by both industry and the FDA. In addition, current barriers for the collection of such samples were detailed and possible solutions for overcoming barriers at sites, as well as globally within countries, were discussed. The importance of international concordance on collection of these samples was emphasized, and potential areas for industry to harmonize sample collection practices. A standalone workshop on issues related to sampling was determined to be a key step for solving issues related to future use sample collection during drug development.
Bibliography
- 1 World Medical Assembly: Recommendation guiding medical doctors in biomedical research involving human subjects. Declaration of Helsinki. June 1964 (Revised 1975).
- 2 The National Research Act: Protection of Human Subjects. Public Law 93-348. 98th Congress. (July 1974).
- 3 The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research: Ethical Principles and Guidelines for the protection of human subjects of research. The Belmont Report (April 1979).
- 4 Department of Health and Human Services, Office for Human Research Protection (OHRP): Protection of Human Subjects. Code of Federal Regulations. Public Welfare. 45 CRF Part 46 July 2009 (Effective date).
- 5 Food and Drugs: Code of Federal Regulations. Department of Health and Human Services. Protection of Human Subjects 21 CRF Part 50 April 2010 (Revised).
- 6 Food and Drugs: Code of Federal Regulations. Department of Health and Human Services. Institutional Review Boards 21 CRF Part 56 April 2010 (Revised).
- 7 Department of Health and Human Services: General Administrative Requirements. Code of Federal Regulations. Public Welfare. (November 2010).
- 8 Department of Health and Human Services: Security and Privacy. Code of Federal Regulations. Public Welfare 45 CRF Part 164 (subpart A and E) (November 2010).
- 9 Pediatric Research Equity Act of 2003. Public Law 108–155. 108th Congress. (December 2003).
- 10 Wendler D: One-time general consent for research on biological samples. BMJ332,544–557 (2006).
- 101 Department of Health and Human Services Online Access. Standards for privacy of individually identifiable health information: final rule, 45 CFR Part 46 (14 July 2009) www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm. (Accessed 14 June 2009)
- 102 Standards for Privacy of Individually Identifiable Health Information: Final Rule, 45 CFR Parts 160 and 164 (14 August 2002) www.hhs.gov/ocr/privacy/hipaa/administrative/privacyrule/privrulepd.pdf
